Correction: Application Fee for 2023 Reminder, CR 114074
Please note the application fee adjustment is for CY 2023, not 2022, as published in a previous message.
DHHS → node
Please note the application fee adjustment is for CY 2023, not 2022, as published in a previous message.
The federal deadline to implement the EVV requirements for Home Health providers delivering services under Section 40 and Hospice providers delivering services under Section 43 is January 1, 2023.
With these EVV deadlines quickly approaching, we continue to offer weekly provider and aggregator trainings and forums. All trainings and forums are online via Microsoft Teams.
Effective January 1, 2023, in accordance with the Centers for Medicare & Medicaid Services (CMS) application fee requirements, MaineCare’s provider enrollment application fee will increase to $688 per enrollment application. This increase will apply to new, reactivating, or revalidating providers, or when adding new service locations to an existing enrollment. You can pay the application fee by credit or debit card at the time of application submission.
As previously shared in our November 17, 2022, bulletin, the Department initiated a rate determination for Section 30, Family Planning Services. As a result of that process, we are now conducting a rate study.
To provide a clear and transparent process for MaineCare rate determinations, with opportunities for robust participation from all interested stakeholders.
We will be updating this page with important dates and progress made on past, current, and future rate determination work. Please check in often, as this site is a work in progress.
This message corrects an earlier message that listed an incorrect to the effective date in the table. All correct dates are now listed.
This bulletin provides notice that the Department initiated a Rate Determination Process* for the National Diabetes Prevention Program (NDPP) in the Spring of 2022, prior to P.L. 2021 Ch. 639 becoming effective. This is a new service that is under development, with the service’s placement within the appropriate section of the MaineCare Benefits Manual still to be determined. The Department will conduct this determination. This initiative is pursuant to P.L. 2021, Ch. 398, Sec.
In a December 8, 2022, announcement, the Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) for the use of Bivalent COVID-19 Vaccines from Pfizer BioN-Tech to be used as the third dose of the